Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's ADD-Vantage

Executive Summary

FDA will review more than 40 drugs in addition to three Lilly antibiotics (Keflin, Kefzol, Mandol) for use in the drug delivery system, Abbott reports

You may also be interested in...



Early Data Support J&J’s COVID-19 Vaccine Push Into Phase III

Johnson & Johnson have released early data putting its COVID-19 vaccine broadly in line with frontrunners from Pfizer and Moderna, but with key advantage of requiring just one injection.

Interview: Has UK Medtech Happened Upon A Perfect Opportunity For Disruptive Regulatory Change?

ABHI’s Phil Brown looks beyond the immediate challenges for UK medtechs on being outside the EU, and to an innovation-friendly, patient-responsive system of future regulation.

Stockwatch: Esperion – Bonfire Of The Surrogates

For a biotech launching its first product the pandemic has compounded the usual pressures of a competitive indication against deeper-pocketed competition.

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel